Indian Journal of Microbiology Microbiology
Bacillus licheniformis as a Novel Therapeutic Approach for Huntington’s Disease in Caenorhabditis elegans
Abstract
The human microbiome plays a crucial role in regulating host health, with microbial dysbiosis increasingly linked to neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease (HD), and amyotrophic lateral sclerosis. Among these, HD is a progressive neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the huntingtin (HTT) gene, leading to abnormal polyglutamine (poly-Q) aggregation and impaired proteostasis. In this study, we explored the neuroprotective potential of Bacillus licheniformis in Caenorhabditis elegans HD models. Worms expressing poly-Q were assessed for key parameters including lifespan, health span, reactive oxygen species (ROS) levels, protein aggregation, and neurotoxicity. Results demonstrated that B. licheniformis feeding reduced poly-Q aggregation in muscle cells and mitigated sensory neuron degeneration. Additionally, treated worms showed enhanced longevity and improved health span. These benefits correlated with the activation of the DAF-16/FOXO transcription factor, heat shock protein HSP-16.2, and antioxidant enzyme SOD-3, indicating improved oxidative stress resistance and proteostasis. Our findings suggest that B. licheniformis confers neuroprotection by modulating stress response pathways and mitigating protein aggregation, highlighting its potential as a therapeutic probiotic for HD and other age-related neurodegenerative conditions.